Repligen Corp. Daily Stock Analysis

Daily Stock Analysis, RGEN, Repligen Corp, priceseries

Repligen Corp. Daily Stock Analysis
Stock Information
Open
179.25
Close
163.66
High
179.50
Low
163.23
Previous Close
178.80
Daily Price Gain
-15.14
YTD High
265.78
YTD High Date
Jan 3, 2022
YTD Low
163.23
YTD Low Date
Mar 7, 2022
YTD Price Change
-94.30
YTD Gain
-36.56%
52 Week High
327.32
52 Week High Date
Sep 23, 2021
52 Week Low
162.29
52 Week Low Date
May 17, 2021
52 Week Price Change
-17.82
52 Week Gain
-9.82%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 7. 2018
38.35
Jun 15. 2018
43.69
28 Trading Days
13.94%
Link
LONG
Aug 17. 2018
49.52
Sep 20. 2018
57.19
23 Trading Days
15.49%
Link
LONG
Apr 25. 2019
57.24
May 13. 2019
67.32
12 Trading Days
17.62%
Link
LONG
Jun 17. 2019
77.50
Jul 16. 2019
83.70
20 Trading Days
8.00%
Link
LONG
Apr 9. 2020
98.95
May 26. 2020
134.74
31 Trading Days
36.17%
Link
LONG
Jul 29. 2020
138.78
Aug 10. 2020
147.78
8 Trading Days
6.49%
Link
LONG
Oct 5. 2020
159.80
Oct 28. 2020
170.87
17 Trading Days
6.93%
Link
LONG
Jan 5. 2021
194.67
Jan 26. 2021
210.04
14 Trading Days
7.90%
Link
LONG
Mar 31. 2021
194.41
Apr 29. 2021
213.30
20 Trading Days
9.71%
Link
LONG
Jul 20. 2021
202.97
Sep 27. 2021
306.69
48 Trading Days
51.10%
Link
Company Information
Stock Symbol
RGEN
Exchange
NasdaqGS
Company URL
http://www.repligen.com
Company Phone
7814499560
CEO
Tony J. Hunt
Headquarters
Massachusetts
Business Address
41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA 02453
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000730272
About

Repligen Corp. engages on the development, production and commercialization of products used in the process of manufacturing biological drugs. It offers upstream solutions, downstream solutions, and analytics. The upstream solutions offers XCell ATF System and cell culture supplements. The downstream solutions includes OPUS pre-packaged chromatography columns; Protein A affinity resins; and Protein A Ligands. The analytics involves ELISA kits. The company was founded by Alexander G. Rich in May 1981 and is headquartered in Waltham, MA.

Description

Repligen Corporation, a bioprocessing company, focuses on the development, production, and commercialization of products used in the production of antibody-based therapeutics, recombinant proteins, and vaccines worldwide. It manufactures various forms of Protein A, a critical component used to purify antibody-based drugs. The company also supplies alternating tangential flow system filtration devices and protein cell culture supplements that are used in clinical and commercial stage manufacturing to enhance biologic drug yields. In addition, it manufactures and sells OPUS pre-packed chromatography columns, which are used in the purification of clinical-stage biologics; and tangential flow filtration cassettes that are used to concentrate clinical and commercial stage biologic drugs. Further, the company has a portfolio of therapeutic product candidates, which include histone deacetylase inhibitor for the treatment of Friedreich's ataxia disease; and RG1068, a synthetic human hormone developed as a novel imaging agent for the detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and other pancreatic diseases. The company sells its bioprocessing products directly and through distributors to various life sciences companies, biopharmaceutical companies, and contract manufacturers. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading